Article in Genes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Christina W KamDepartment of Pharmacology, Weill Medical College, Cornell University, New York, NY 10065, USA.
Jason G DumelieDepartment of Pharmacology, Weill Medical College, Cornell University, New York, NY 10065, USA.ORCID 0000-0002-6926-4843
Gabriele CiceriThe Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA.
Wang-Yong YangDepartment of Chemistry and Physics, University of Tennessee at Chattanooga, Chattanooga, TN 37403, USA.ORCID 0000-0002-1839-631X
Matthew D DisneyDepartment of Chemistry, The Scripps Research Institute, Scripps Florida, Jupiter, FL 33458, USA.
Lorenz StuderThe Center for Stem Cell Biology, Sloan Kettering Institute for Cancer Research, New York, NY 10065, USA.
Samie R JaffreyDepartment of Pharmacology, Weill Medical College, Cornell University, New York, NY 10065, USA.ORCID 0000-0003-3615-6958
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Design of Precision Small Molecules Targeting RNA Repeating Transcripts to Manipulate and Study Disease BiologyR35NS116846 · NINDS · UNIVERSITY OF FLORIDA · PI Matthew D Disney · 2020 to 2026
$9.4M
New mechanisms and technologies for understanding post-transcriptional gene regulation in neuronsR35NS111631 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAMIE R JAFFREY · 2019 to 2026
$8.6M
Novel strategies for induction of aging in human PSC-derived lineages for modeling Alzheimer's DiseaseR01AG054720 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI Doron Betel, LORENZ P. STUDER · 2017 to 2026
$4.5M
Engineering RNA-activated fluorescence switches for RNA imaging and analyte sensiR01NS064516 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JAFFREY, SAMIE R · 2009 to 2018
$3.6M
Training Program in Developmental BiologyT32HD060600 · NICHD · WEILL MEDICAL COLL OF CORNELL UNIV · PI BAO, ZHIRONG, STUHLMANN, HEIDI · 2010 to 2024
$3.5M
Cell Intrinsic and Extrinsic Factors Driving Maturation in Human PSC-derived NeuronsR01NS128087 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI LORENZ P. STUDER · 2023 to 2026
$2.6M
Manipulating autophagy in human neurons to determine subtype-specific neurodegenerative disease phenotypesR21NS116545 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI STUDER, LORENZ P. · 2020 to 2020
$494k
Ultra-sensitive multi-mode laser-scanning imaging systemS10OD030335 · OD · WEILL MEDICAL COLL OF CORNELL UNIV · PI JAFFREY, SAMIE R · 2021 to 2021
objectivesFragile X syndrome (FXS) is a disease of pathologic epigenetic silencing induced by RNA. In FXS, an expanded CGG repeat tract in the
methodsThis study uses immunofluorescence and fluorescent in situ hybridization (FISH) to measure whether
resultsIn this study, we find that 2HE-5Nme maintains
conclusionsThese results demonstrate that an RNA-binding small molecule can achieve gene-specific epigenetic control and provide an approach for the restoration of FMRP in FXS neurons.
Indexed as
Epigenesis, GeneticFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeNeuronsAnimalsCells, CulturedDecitabineMiceTrinucleotide Repeat ExpansionDecitabineFmr1 protein, mouseFragile X Messenger Ribonucleoprotein 1epigeneticsfragile X syndromeRNA-binding small molecule
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Sustained Epigenetic Reactivation in Fragile X Neurons with an RNA-Binding Small Molecule. · full record | OpenQuestion